Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Impact of Cellular Immune Function on Prognosis of Lung Cancer Patients after Cytokine-induced Killer Cell Therapy

  • Jin, Congguo (Cancer Research Institute, Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) ;
  • Li, Jia (Cancer Research Institute, Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) ;
  • Wang, Yeying (Epidemiology and Biostatistics Department, School of Public Health, Kunming Medical University) ;
  • Chen, Xiaoqun (Cancer Research Institute, Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) ;
  • Che, Yanhua (Breast Disease Center, The First Peoples' Hospital of Kunming, Yunnan Province) ;
  • Liu, Xin (Cancer Research Institute, Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) ;
  • Wang, Xicai (Cancer Research Institute, Yunnan Cancer Hospital (The 3rd Affiliated Hospital of Kunming Medical University)) ;
  • Sriplung, Hutcha (Epidemiology Unit, Faculty of Medicine, Prince of Songkla University)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Aims: To investigate changes in cellular immune function of patients with lung cancer before and after cytokine-induced killer (CIK) cell therapy and to identify variation effects on overall survival (OS) and progression-free survival (PFS). Materials and Methods:A total of 943 lung cancer patients with immune dysfunction were recruited from January 2002 to January 2010, 532 being allocated to conventional therapy and 411 to CIK therapy after a standard treatment according to the NCCN Clinical Practice Guidelines. All the patients were investigated for cellular immune function before and after therapy every three months. and clinical prognostic outcomes were analyzed. Results: After six courses of treatment, immune function was much improved in patients receiving CIK cells therapy as compared to controls. The percentages of recurrence and/or metastases for patients undergoing CIK cell therapy was 56.2% and 49.1% respectively but 78.6% and 70.3% among controls (p<0.001). The median OS times for CIK cell therapy and control groups were 48 and 36 months respectively. The OS rates at 12, 36, 60, 84 months in CIK treated patients were 97.8%, 66.9%, 27.7%, and 4.1% while they were 92.3%, 44.5%, 9.2%, and 1.5% in controls. OS and PFS were significantly different by log rank test between the two groups and across the three immune improvement classes. Conclusions: The immune function of lung cancer patients was improved by CIK cell therapy, associated with an increase in the OS rate and extension of the time to recurrence and/or metastasis.

Keywords

References

  1. Blattman JN, Greenberg PD (2004). Cancer immunotherapy: a treatment for the masses. Science, 305, 200-5. https://doi.org/10.1126/science.1100369
  2. Chen W, Zhang R, Zhang S, et al (2013). The incidences and mortalities of major cancers in China, 2009. Chin J Cancer, 32, 106-12. https://doi.org/10.5732/cjc.013.10018
  3. Dougan M, Dranoff G (2009). Immune therapy for cancer. Annu Rev Immunol, 27, 83-117. https://doi.org/10.1146/annurev.immunol.021908.132544
  4. Hontscha C, Borck Y, Zhou H, et al (2011). Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol, 137, 305-10. https://doi.org/10.1007/s00432-010-0887-7
  5. Jemal A, Bray F, Melissa M, et al (2011). Global cancer statistics. A Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  6. Jiang J, Xu N, Wu C, et al (2006). Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res, 11, 2237-42.
  7. Jiang JT, Shen YP, Wu CP, et al (2010). Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol, 11, 6155-62.
  8. Jin CG, Chen XQ, Li J, et al (2013). Moderating effects and maintenance of lung cancer cellular immune functions by CIK cell therapy. Asian Pac J Cancer Prev, 14, 6229-34.
  9. Kim HM, Lim J, Park SK, et al (2007). Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol, 7, 1802-7. https://doi.org/10.1016/j.intimp.2007.08.016
  10. Li R, Wang C, Liu L, et al (2012). Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother, 61, 2125-33. https://doi.org/10.1007/s00262-012-1260-2
  11. Lin J, Zhu H, Lu X, et al (2010). Autologous cytokine-induced killer cells in the treatment of multiple myeloma concomitant with lung cancer and paraneoplastic dermatoses. Intern Med, 49, 2341-6. https://doi.org/10.2169/internalmedicine.49.3996
  12. Olioso P, Giancola R, Di Riti M, et al (2009). Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol, 11, 130-9.
  13. Schmidt-Wolf IG, Finke S, Trojaneck B, et al (1999). Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer, 11, 1009-16.
  14. Schmidt-Wolf IG, Lefterova P, Mehta BA, et al (1993). Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol, 21, 1673-9.
  15. Schmidt-Wolf IG, NR, Kiem HP, et al (1991). Use of a SCID mouse/human lymphoma model to evaluate cytokineinduced killer cells with potent antitumor cell activity. J Exp Med, 174, 139-49. https://doi.org/10.1084/jem.174.1.139
  16. Stroncek D, Berlyne D, Fox B, et al (2010). Developments in clinical cell therapy. Cytotherapy, 12, 425-8. https://doi.org/10.3109/14653240903511952
  17. Sun Y, Liao M, Cheng G (2011). NCCN nonsmall-cell lung cancer clinical practice guidline:Chinese edition vesion. Beijing.
  18. Wu C, Jiang J, Shi L, et al (2008). Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res, 11, 3997-4002.
  19. Zheng YW, Li RM, Zhang XW, et al (2013). Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest, 31, 197-205. https://doi.org/10.3109/07357907.2013.775294
  20. Zhong R, Han B, Zhong H (2013). A prospective study of the efficacy of a combination of autologous endritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol, [Epub ahead of print].

Cited by

  1. Cellular Immunity, Physical Activity and Improve Clinical Efficacy in Advanced Cancer Patients Unresponsive to Conventional Treatments vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2419
  2. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis vol.34, pp.26, 2016, https://doi.org/10.1200/JCO.2015.66.3955
  3. Change in Palliative Performance Scale (PPS) Predicts Survival in Patients with Terminal Cancer vol.20, pp.4, 2017, https://doi.org/10.14475/kjhpc.2017.20.4.235
  4. Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer vol.36, pp.1, 2017, https://doi.org/10.1186/s40880-017-0260-1
  5. Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy vol.8, pp.1664-3224, 2017, https://doi.org/10.3389/fimmu.2017.00774